A Phase I/II Trial of HER2 Vaccine–Primed ...Treatment Refractory HER2–Overexpressing
This is a very hopeful news for Her2 Met patients!
A Phase I/II Trial of HER2 Vaccine–Primed Autologous T-Cell Infusions in Patients with Treatment Refractory HER2–Overexpressing Breast Cancer https://aacrjournals.org/clincancerr...dFrom=fulltext Beyond Neoantigens: Antigens Derived from Tumor Drivers as Cancer Vaccine Targets https://aacrjournals.org/clincancerr...ved-from-Tumor |
All times are GMT -7. The time now is 10:42 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021